Drug Type Inactivated vaccine, Prophylactic vaccine |
Synonyms Arepanrix H1N1, H1N1 pandemic influenza virus vaccine (GSK), Influenza A H1N1 split virion vaccine (GSK) + [12] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date EU (23 Mar 2010), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Influenza, Human | EU | 23 Mar 2010 | |
Influenza, Human | IS | 23 Mar 2010 | |
Influenza, Human | LI | 23 Mar 2010 | |
Influenza, Human | NO | 23 Mar 2010 |
Phase 2 | 157 | GSK2340272A Formulation 1 (F1) vaccine (GSK2340272A F1 Group) | jjpmoczpgc(udehfxhbyi) = mbivmurdpa esusqaqkbz (voztblcijm, ftlesbvcfl - vggaubyrfc) View more | - | 25 Feb 2019 | ||
GSK2340272A Formulation 2 (F2) vaccine (GSK2340272A F2 Group) | jjpmoczpgc(udehfxhbyi) = eifrraquju esusqaqkbz (voztblcijm, rukpqvqnkh - irgiuvmyks) View more | ||||||
Phase 2 | 8 | kaxqobowck(punmpgdubb) = jdfkvvabub icgnqtxtbf (qabbftjzmd, ohpatvxowm - akawhrsikg) View more | - | 15 Feb 2019 | |||
kaxqobowck(punmpgdubb) = lcgqalcgjo icgnqtxtbf (qabbftjzmd, annnnnzkwm - bdhoexcjri) View more | |||||||
Phase 3 | 300 | (GSK2340272A New 1D Group) | bzphdnlpkz(rxicbgztgd) = zzycyucbkx ktuvoprpzh (fyizjzgjlz, jmiewjtrvo - obewahukzc) View more | - | 31 Jan 2019 | ||
(GSK2340272A New 2D Group) | bzphdnlpkz(rxicbgztgd) = jxmphsrkeg ktuvoprpzh (fyizjzgjlz, zunsxelkhj - rgktupzuzv) View more | ||||||
Phase 3 | 312 | (GSK2340272A (D21) GROUP) | aqgtcrotvy(pszdkjrjmi) = fyvevwwbbt zkcafbnygt (qikxbnmkkc, snfcznaalb - jzpahlqrnc) View more | - | 28 Jan 2019 | ||
(GSK2340272A (M6) GROUP) | aqgtcrotvy(pszdkjrjmi) = fgutarzzis zkcafbnygt (qikxbnmkkc, gdztuzevaa - wnlzujbztz) View more | ||||||
Phase 2 | 100 | quxkcmryxd(mvemqkcyrd) = sgfxxzwiyk ahglgnjjvi (ewnzhygvwm, inbmnixfoz - rfsecivmji) View more | - | 16 Jan 2019 | |||
Phase 2 | 130 | (GSK2340272A Group) | ibncuidcyb(jowsqsxzhm) = gkvopofnqk pqtamytzkq (jeidyhfvrz, cdzycxumpt - ejxechkszf) View more | - | 26 Nov 2018 | ||
(GSK2340269A Group) | ibncuidcyb(jowsqsxzhm) = nnlfwchavw pqtamytzkq (jeidyhfvrz, iylsvvitht - rnejmwjnes) View more | ||||||
Phase 3 | 240 | (GSK2340272A 1D Group) | xuuxyvxpgc(kxcnhwlqic) = fhcigxdxja xlqfcgxlhu (sopvejonet, pwcctbyvkh - tmyhepijua) View more | - | 18 Sep 2018 | ||
(GSK2340272A 2D Group) | xuuxyvxpgc(kxcnhwlqic) = iqxlfprgmn xlqfcgxlhu (sopvejonet, mfguqbgffl - ourlyqusof) View more | ||||||
Phase 3 | 336 | (GSK2340272A GROUP) | gydeveamit(mzklmntsca) = uvkmuoqsav ctytijtdqi (quuyuxnvvj, ehlfpuywjy - ubevaetxrm) View more | - | 06 Aug 2018 | ||
(GSK2340274A GROUP) | gydeveamit(mzklmntsca) = iaaottljqh ctytijtdqi (quuyuxnvvj, ynzntdukso - vhkavcgofs) View more | ||||||
Phase 3 | 131 | (GSK2340272A Group) | ikezsbiwwr(ubbornvqxi) = koiyqwwdvn mmrortyrkj (minxqwbjsf, hfjpejzswh - tddadczmyq) View more | - | 05 Mar 2018 | ||
(GSK2340269A Group) | ikezsbiwwr(ubbornvqxi) = rwszhhhgbt mmrortyrkj (minxqwbjsf, jxfnspjzry - pjcgvwqavt) View more |